BioNTech CEO Sahin sells 20,500 shares at $96.3
BioNTech’s CEO Ugur Sahin sold 20,500 shares under a pre-arranged Rule 10b5-1 trading plan and remains a large shareholder through substantial direct and indirect holdings.
Rhea-AI Filing Summary
BioNTech SE (BNTX) reports that Chief Executive Officer and ten percent owner Ugur Sahin sold 20,500 Ordinary Shares on September 10, 2026 in an open-market or private transaction at $96.31 per share, under a Rule 10b5-1 trading plan established on June 3, 2026. Following this sale, he holds 688,209 Ordinary Shares directly and 39,218,111 Ordinary Shares indirectly through Medine GmbH, including 106,721 shares held in trust where Medine GmbH has voting but not dispositive power and Sahin may be deemed to beneficially own those shares.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 20,500 shares
Net Sell
2 txns
Insider
Sahin Ugur
Role
Chief Executive Officer
Sold
20,500 shs ($1.97M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 20,500 | $96.3067 | $1.97M |
| holding | Ordinary Shares F1 | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 688,209 shares (Direct);
Ordinary Shares — 39,218,111 shares (Indirect, See Footnote)
Footnotes (1)
- F1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.
Key Figures
Shares sold: 20,500 shares
Sale price per share: $96.3067 per share
Direct holdings after transaction: 688,209 shares
+3 more
6 metrics
Shares sold
20,500 shares
Ordinary Shares sold by Ugur Sahin on September 10, 2026
Sale price per share
$96.3067 per share
Price for the 20,500 Ordinary Shares sold on September 10, 2026
Direct holdings after transaction
688,209 shares
Ordinary Shares directly held by Ugur Sahin following the sale
Indirect holdings after transaction
39,218,111 shares
Ordinary Shares indirectly held through Medine GmbH
Shares held in trust
106,721 shares
Ordinary Shares held in trust where Medine GmbH has voting but not dispositive power
Rule 10b5-1 plan adoption date
June 3, 2026
Date Ugur Sahin established the trading plan used for the reported sale
Key Terms
Rule 10b5-1 trading plan, dispositive power, beneficially own
3 terms
Rule 10b5-1 trading plan regulatory
"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
dispositive power financial
"Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
beneficially own financial
"The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BioNTech (BNTX) report for CEO Ugur Sahin?
CEO Ugur Sahin sold 20,500 Ordinary Shares of BioNTech on September 10, 2026 in a sale reported as an open-market or private transaction, at a price of $96.31 per share, under a Rule 10b5-1 trading plan.
What are Ugur Sahin’s remaining direct holdings in BioNTech (BNTX) after this transaction?
After the reported sale, Ugur Sahin directly holds 688,209 Ordinary Shares of BioNTech. This figure is stated as his total direct ownership following the transaction on September 10, 2026.
What indirect BioNTech (BNTX) holdings does Ugur Sahin have through Medine GmbH?
Indirectly, 39,218,111 Ordinary Shares are held by Medine GmbH, of which Ugur Sahin is the sole shareholder. The filing states he may be deemed to beneficially own these shares, including 106,721 shares held in trust.
What does the Form 4 say about the Rule 10b5-1 trading plan for BioNTech (BNTX)?
The Form 4 states the sales were effected pursuant to a Rule 10b5-1 trading plan established by Ugur Sahin on June 3, 2026, indicating the transactions were pre-arranged under that plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
